Mae Shieh is an accomplished leader in business development and public health, currently serving as the Head of Business Development and Decarbonisation Project Lead at the Drugs for Neglected Diseases initiative (DNDi) since 2018. In this role, Mae has been instrumental in forming partnerships to ensure sustainable access to medicines for neglected populations, and is also driving efforts to reduce DNDi's environmental footprint. Previously, Mae held various senior positions at GSK Vaccines Institute for Global Health and Novartis, where contributions included the development of commercialization strategies for neglected disease vaccines and the establishment of significant partnerships for research initiatives. Mae's educational background includes an MBA from INSEAD and a Master's degree in International Public Health from the University of Basel, complemented by a Bachelor's degree in Electrical Engineering from Purdue University.
This person is not in any teams
This person is not in any offices
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.